Predictors of rate of cognitive decline in patients with amnestic mild cognitive impairment

Brittany Cerbone1, Paul J Massman1, Paulina A Kulesz1

  • 1Department of Psychology, University of Houston, Houston, TX, USA.

Abstract

Insights

Amnestic mild cognitive impairment (MCI) progression is faster in ApoE ε4 carriers and those with poorer baseline executive function and memory. Lower depression at baseline predicted faster decline, contrary to expectations.

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Science

Background:

  • Amnestic mild cognitive impairment (MCI) is a significant risk factor for Alzheimer's disease (AD).
  • Predictors of MCI conversion to AD are well-researched, but predictors of the *rate* of decline are less understood.
  • Understanding factors influencing decline rate is crucial for prognosis and targeted interventions.

Purpose of the Study:

  • To systematically examine predictors of cognitive decline rate in individuals with amnestic MCI.
  • To investigate the role of age, ApoE ε4 genotype, baseline cognitive performance, and neuropsychiatric severity.
  • To identify individuals at higher risk for rapid progression to Alzheimer's disease.

Main Methods:

  • Longitudinal study of 151 participants with amnestic MCI.
  • Baseline assessments included cognitive function and neuropsychiatric status.
  • Follow-up assessments over a mean interval of 1.61 years to measure dementia severity changes.

Main Results:

  • ApoE ε4 carriers showed faster decline on dementia severity measures than non-carriers.
  • Lower baseline executive function and greater memory impairment predicted faster decline.
  • Individuals with less severe depression at baseline experienced more rapid decline, contrary to the hypothesis.

Conclusions:

  • Baseline ApoE ε4 status, executive function, memory impairment, and depression levels are significant predictors of cognitive decline rate in amnestic MCI.
  • These findings are clinically relevant for prognostic assessments and guiding therapeutic strategies.
  • Further research can leverage these predictors to develop interventions aimed at slowing AD progression.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
438
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
662
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
437
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
668
Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
341